Certolizumab and Lower Extremity Lymph Flow in Rheumatoid Arthritis (RA)
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This open-label pilot study will select subjects who are inadequate responders to
methotrexate. These subjects will receive certolizumab subcutaneously on a monthly basis for
six months. The study is attempting to determine the following:
1. Is lymphatic flow altered in the extremities of RA patients with an inflamed knee?
2. Is resolution of synovitis associated with a restoration of lymphatic flow and lymph
node volume following therapy with certolizumab?
3. Can Doppler ultrasound be used to detect and follow alterations of lymph node size?